Search Site

MS Research

For those interested in research, please contact Kaho Onomichi (212-305-9155, ko2418@cumc.columbia.edu) or Eva Gelernt (212-342-4649, erg2144@cumc.columbia.edu).

Currently Recruiting

  • ARISE: Multi-center, randomized, double-blinded assessment of Tecfidera in extending the time to a first attach in radiologically isolated syndrome (RIS)
    Patients with a current RIS diagnosis are being recruited for a clinical trial to assess the efficacy of Tecfidera in extending the time to first attack (acute or progressive) over the course of two years.

  • CIRCLES: Collaborative International Research in Clinical and Longitudinal Experience for Neuromyelitis Optica (NMO) Studies
    First-degree relatives of NMO patients or healthy volunteers are being recruited for a biorepository study over the course of five years. This study aims to create a longitudinal collection of samples and data from NMO and control patients to be utilized in future NMO research.

  • AAMS: MRI predictors of disease and disability progression in African Americans with Multiple Sclerosis
    African American and Caucasian RRMS patients are being recruited for a 4-year-long study to evaluate the difference in disease progression and disability between those of different races.

  • The PhenoGenetic Project at the Columbia University Medical Center
    Healthy volunteers are being recruited for a study to evaluate the relationship between genes and the immune system. This study spans five years, with study visits every three months.

  • GEMS: Integrating Genetic and Environmental Risk Scores into an Algorithm to Predict Multiple Sclerosis
    Frist-degree relatives of Multiple Sclerosis are being recruited for a longitudinal study that will collect data and biological specimens over the span of 20 years. This information will be used to identify the genetic, environmental, and immune profiles that may increase a person’s risk of developing MS.

  • TREAT-MS
    RRMS patients are being recruited to evaluate if originating a patient’s MS care with a more aggressive approach via a high-efficacy MS medicine (as opposed to the traditionally practiced lower-risk, low-efficacy first-line treatment) decreases patients’ disability accumulation.

  • Tysbari Extended Interval Dosing
    Patients with a current RRMS diagnosis are being recruited to assess the efficacy of extended interval dosing with Tysabri: every 4 weeks, every 6 weeks, and every 8 weeks. Through blood and cognitive results, this study aims to see if reducing the frequency of Tysabri dosing to every 6 or 8 weeks leads to different clinical MS outcomes.

  • Testosterone
    Male MS patients with low testosterone are being recruited to assess the efficacy of testosterone supplementation on MS disease course.

  •  MS GENETICS

  •  E-Support Groups

Active But Not Currently Recruiting

  • BIOTIN: Effect of MD1003 in Progressive Multiple Sclerosis: a randomized double blind placebo controlled study
    Patients with SPMS or PPMS are being recruited for a Phase III clinical trial to evaluate the effectiveness of high-dose Biotin over the span of 27 months. 

  • Cognitive Reserve
    RRMS patients and healthy volunteers have been recruited to examine factors related to protection from cognitive decline over time. This is being evaluated by comparing MRI and cognitive-battery results from a baseline visit and a follow-up visit, conducted 3 years later.

  • CHORDS: An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to An Adequate Course of Disease-Modifying Treatment
    Patients with RRMS who have had a suboptimal response to an adequate course of a disease-modifying treatment have been enrolled in a two-year, Phase III clinical trial to assess the efficacy of ocrelizumab in this population.

  • ENSEMBLE: An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early Stage Relapsing Remitting Multiple Sclerosis
    Treatment naive patients with a current RRMS diagnosis have been enrolled in a Phase III clinical trial to evaluate the efficacy of ocrelizumab in early stages RRMS over the course of 4.5 years. 

  • Resting State Functional Connectivity as a Predictor of Memory Decline in Multiple Sclerosis
    RRMS patients have been enrolled in a cognitive research study to evaluate the changes in memory and cognition between a baseline visit and a follow-up visit, conducted 3+ years later.

Closed Studies

  • A Randomized, Double-Blind, Placebocontrolled Study to Evaluate the Safety, Tolerability and Activity Of Ibudilast (Mn-166) in Subjects With Progressive Multiple Sclerosis (Condition: Multiple Sclerosis)

  • A Randomized Controlled Trial of Aspirin in Relapsing-Remitting Multiple Sclerosis (RRMS)

  • Educational Outcomes of Cognition in Pediatric Multiple Sclerosis

  • Reserve Against Primary-Progressive Multiple Sclerosis (PPMS) Disability

  • Resting State Functional Connectivity as a Predictor of Memory Decline in Multiple Sclerosis (Condition: Multiple Sclerosis)

  • Development of a test for autoantibodies in Susac Syndrome (Condition: Susac Syndrome)

  • A Randomized Controlled Trial of Vitamin D Supplementation in Multiple Sclerosis (Condition: Multiple Sclerosis)
     
  • RESPOND: An Observational Study of Tecfidera in relapsing-remitting multiple sclerosis (RRMS).
     
  • A Study Comparing Copaxone and Estriol vs. Copaxone Alone in People With Relapsing-Remitting Multiple Sclerosis (Condition: Multiple Sclerosis)
     
  • Effectiveness and Safety of Fingolimod (FTY720) in Patients With Relapsing-Remitting Multiple Sclerosis (Condition: Multiple Sclerosis)
     
  • A Study Comparing the Combination of Avonex and Copaxone vs. Either Medication Alone in People with Relapsing-Remitting MS (Condition: Multiple Sclerosis)
     
  • A Study of the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (Condition: Multiple Sclerosis)
     
  • A Study to Evaluate the Safety and Effectiveness of MBP8298 in People with Secondary Progressive MS (Condition: Multiple Sclerosis)
     
  • Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR (Condition: Multiple Sclerosis)
     
  • Safety and Tolerability of Rituximab in Neuromyelitis Optica (Condition: Neuromyelitis Optica)